Session | Vaccine preventable disease

Value of the Information & Strength of the Argument

The session provides valuable insights into the operational challenges and scientific evidence behind vaccination strategies in humanitarian settings. The presentation of the Men5CV effectiveness study is a strong example of real-world evidence generation, with clear methodology and results. The argumentation is solid, grounded in field data and references to WHO recommendations. However, some discussions are more opinion-based, particularly regarding funding and policy, which are not always supported by detailed data.

Scientific Rigor, Source Quality, Title Accuracy

The session references several studies and WHO guidelines, but specific citations are not always provided in the transcript. The title is broad but accurate. The content is scientifically rigorous, with experts from Epicentre/MSF presenting peer-reviewed research. The adequacy between title and content is good, though the title could be more specific. No comments were provided for analysis.

The title is generic but accurately reflects the session's focus on vaccine-preventable diseases, specifically meningitis and measles.

7/10

The session is presented by experts from Epicentre/MSF, with references to published studies and WHO recommendations. However, it is a recorded session with limited visual aids, and some data are presented without full methodological detail.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 00:00Introduction to the session on vaccine-preventable diseases by Epicentre/MSF.
• 02:00Vincent reviews the history of meningitis research and control, including the shift to preventive vaccination.
• 10:00Discussion on the introduction of the pentavalent meningococcal vaccine (Men5CV) and its prequalification by WHO.
• 20:00Mida presents the case-control study on Men5CV effectiveness during an outbreak in Niger.
• 30:00Results of the vaccine effectiveness study: 88% overall efficacy, 91% for serogroup C.
• 40:00Discussion on the duration of protection and the need for broader age groups in vaccination campaigns.
• 50:00Vincent introduces the measles control section, highlighting the importance of early vaccination and targeting high-risk populations.
• 1:00:00Discussion on integrating clinical management with vaccination for measles and the role of rapid diagnostic tests.

• WHO prequalification of Men5CV — Mentioned as the basis for the introduction of the pentavalent vaccine.

• WHO prequalification of Men5CV — Supports the introduction of the vaccine.